-+ 0.00%
-+ 0.00%
-+ 0.00%

Berry Tianheng (688506.SH) subsidiary receives second US$250 million milestone payment from BMS

Zhitongcaijing·11/17/2026 11:25:07
Listen to the news

Zhitong Finance App News, Baili Tianheng (688506.SH) announced that on December 11, 2023, SystimMune, a wholly-owned subsidiary of the company, and Bristol-Myers Squibb (“BMS”, NYSE code: BMY) reached a global strategic cooperation agreement on the “iza-bren” (iza-bren) project. The company has received an initial payment of $800 million from BMS and the first milestone payment of $250 million between 2024 and 2025.

Recently, Systimmune received the second milestone payment of US$250 million from BMS (the actual payment amount is subject to deduction of bank charges). Up to now, the company has received a total of 1.3 billion US dollars in payments under the cooperation agreement. Under the partnership agreement, the company will also be eligible for additional payments of up to $7.1 billion after reaching specific development, registration, and sales milestones.